
BDTX Stock Forecast & Price Target
BDTX Analyst Ratings
Bulls say
Black Diamond Therapeutics Inc is positioned favorably due to its ongoing development of targeted therapies, specifically in addressing oncogenic mutations, with products like BDTX-4933 and BDTX-1535 in its pipeline. Positive outcomes in objective response rates (ORR) anticipated in the second half of 2025 could lead to projected sales of approximately $500-750 million, reflecting a strong market potential. Furthermore, valuations for similar oncology acquisitions suggest that the company could experience substantial upside, estimated at 3-6 times its current valuation, based on M&A proxy data.
Bears say
The negative outlook on Black Diamond Therapeutics Inc. is primarily driven by significant risks associated with its clinical trials, specifically the potential for disappointing efficacy and safety outcomes for its lead candidate, Silevertinib. Additionally, unforeseen delays in research and development, as well as regulatory or commercial challenges, may hinder the company's progress and operational viability. The competitive landscape in the non-classical EGFR mutation non-small cell lung cancer space further exacerbates these concerns, alongside the critical need for sufficient capital to fund ongoing research initiatives.
This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BDTX Analyst Forecast & Price Prediction
Start investing in BDTX
Order type
Buy in
Order amount
Est. shares
0 shares